MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody (MAB) developed to neutralize the rabies virus.
Rabies is essentially 100% fatal, with over 10 million people exposed worldwide and kills 55,000 people or so each year. Post-exposure treatment can be very effective. This usually includes a specific gamma globulin mixture to neutralize the virus.
However, this can be very expensive. So they have developed a monoclonal antibody that neutralizes the rabies virus, preventing it from having any deleterious effect.
If this is demonstrated to be effective and safe, it could make it much easier for countries such as India to deal with rabies exposure.